The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) trial compared
tirofiban with heparin in the treatment of 3,232 patients. The admission criteria
were chest pain within the preceding 24 hours and either electrocardiographic changes
(ST depression in 32%), transient (<20 minutes) ST elevation or T-wave inversion (in
75%), elevated cardiac enzymes, or a history of coronary artery disease.
1
The drugs were infused in a double-blind manner for a total of 48 hours. In addition,
patients received aspirin therapy.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
[No authors listed]. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498–1505.
- Management of intermediate coronary syndrome.Am J Cardiol. 2000; 85: 21B-26B
[No authors listed]. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;38:1488–1497.
Article Info
Identification
Copyright
© 2000 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.
